ATOS Key Statistics, Chart & Performance
The current stock price of ATOS is 5.03 USD. In the past month the price decreased by -46.6%. In the past year, price decreased by -53.92%.
ATOS Technical Analysis
ATOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATOS. ATOS has a great financial health rating, but its profitability evaluates not so good.
ATOS Financial Highlights
Over the last trailing twelve months ATOS reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.02% | ||
| ROE | -60.62% | ||
| Debt/Equity | 0 |
ATOS Forecast & Estimates
ATOS Ownership
ATOS Latest News, Press Relases and Analysis
ATOS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.77 | 383.716B | ||
| AMGN | AMGEN INC | 16.3 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.72 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.88 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.45 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.83 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.09 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ATOS
Company Profile
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Company Info
ATOSSA THERAPEUTICS INC
1448 Nw Market Street, Suite 500
Seattle WASHINGTON 98104 US
CEO: Steven C. Quay
Employees: 13
Phone: 12065880256
ATOSSA THERAPEUTICS INC / ATOS FAQ
What does ATOS do?
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Can you provide the latest stock price for ATOSSA THERAPEUTICS INC?
The current stock price of ATOS is 5.03 USD. The price decreased by -4.91% in the last trading session.
What is the dividend status of ATOSSA THERAPEUTICS INC?
ATOS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATOS stock?
ATOS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for ATOSSA THERAPEUTICS INC?
ATOSSA THERAPEUTICS INC (ATOS) currently has 13 employees.
Can you provide the upcoming earnings date for ATOSSA THERAPEUTICS INC?
ATOSSA THERAPEUTICS INC (ATOS) will report earnings on 2026-03-23, after the market close.